Compare NICE & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NICE | ABVX |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | Israel | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.6B |
| IPO Year | 1996 | N/A |
| Metric | NICE | ABVX |
|---|---|---|
| Price | $106.25 | $110.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $168.46 | $112.83 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 11-13-2025 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.79 | N/A |
| EPS | ★ 8.79 | N/A |
| Revenue | ★ $2,880,503,000.00 | $7,073,400.00 |
| Revenue This Year | $9.20 | $6.80 |
| Revenue Next Year | $6.96 | N/A |
| P/E Ratio | $12.39 | ★ N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $99.00 | $4.77 |
| 52 Week High | $193.52 | $130.25 |
| Indicator | NICE | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 50.41 |
| Support Level | $104.13 | $114.06 |
| Resistance Level | $109.24 | $130.25 |
| Average True Range (ATR) | 5.60 | 6.53 |
| MACD | -0.05 | -1.06 |
| Stochastic Oscillator | 19.19 | 35.29 |
NICE Ltd is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.